Ibrutinib CAS 936563-96-1 Kuchena >99.5% (HPLC) API Featured Image

Purogiramu inonzi Ibrutinib CAS 936563-96-1 Purity >99.5% (HPLC)

Tsanangudzo Pfupi

Kemikari Zita: Ibrutinib

CAS: 936563-96-1

Kuchena:> 99.5% (HPLC)

Chitarisiko: Chichena kune Off-White Crystal Powder

Ibrutinib inonzi BTK inhibitor inoshandiswa kurapa Chronic Lymphocytic Leukemia (CLL) uye Mantle Cell Lymphoma (MCL)

Bata: Dr. Alvin Huang

Nharembozha/Wechat/WhatsApp: +86-15026746401

E-Mail: alvin@ruifuchem.com

Tumira email kwatiri

Product Detail

Product Tags

Tsanangudzo:

Chemical Properties:

Chemical Name	Ibrutinib
Mashoko anoreva zvakafanana	1-[(3R)-3--[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1- Poshi;PCI-32765
Nhamba yeCAS	936563-96-1
Stock Status	MuStock, Kugadzirwa Kunokwira Kusvika Matani
Molecular Formula	C25H24N6O2
Molecular Weight	440.50
Brand	Ruifu Chemical

Zvinotsanangurwa:

Item	Zvinotsanangurwa
Chitarisiko	Ichena kune Off-White Crystal Powder
Identification	IR;HPLC
Kurasika paKuomesa	<0.50%
Residue paIgnition	≤0.10%
Heavy Metals (as Pb)	≤20ppm
Chero Kusachena Kumwe	≤0.20%
Zvose Zvisina Kuchena	<0.50%
Kuchena / Analysis Method	>99.5% (HPLC)
Test Standard	Enterprise Standard
Usage	API

Package & Kuchengeta:

Package: Bhodhoro, Aluminium foil bag, 25kg/Cardboard Drum, kana zvinoenderana nezvinodiwa nemutengi.

Storage Condition:Chengetedza mumidziyo yakavharwa panzvimbo inotonhorera uye yakaoma;Dzivirira kubva kuchiedza uye unyoro.

Zvakanakira:

FAQ:

Application:

Ibrutinib (CAS: 936563-96-1) inhibitor yeBruton tyrosine kinase (BTK) yekurapa kwekusingaperi lymphocytic leukemia (CLL) uye mantle cell lymphoma (MCL).Zvose MCL neCLL ndezveB-cell non-Hodgkin's lymphoma, iyo inoramba uye inokurumidza kudzoka zvakare.Iyo inowanzoshandiswa chemoimmunotherapy haina kunangwa, uye giredhi 3 kana 4 maitiro akashata anowanzoitika.Ibrutinib inogona kusanganiswa neBTK, iyo inofanirwa kuumbwa, kusiyanisa, kutaurirana uye kurarama kweB lymphocytes, uye zvisingachinjiki inhibisa basa reBTK, zvinobudirira kudzivisa kupararira uye kurarama kwemasero emarara.Uye zvakare, inokurumidza kunyura mushure mekutonga nemuromo, iyo yakanyanya plasma concentration inosvika 1 ~ 2h, uye maitiro akashata ari giredhi 1 kana 2, inova sarudzo nyowani yekurapa CLL neMCL.Musi waNovember 13, 2013, iyo US FDA yekumhanyisa kambani yakatenderwa yeJohnson & Johnson neUnited States Imbruvica (zita rinowanzozivikanwa: Ibrutinib) yekurapa mantle cell lymphoma (MCL).Ibrutinib, yakapihwa budiriro yeChimiro cheTherapy neFDA muna Kukadzi 2013 uye yakatenderwa kuMCL musi waMbudzi 13, 2013 uye CLL musi waKukadzi 12, 2014, zvichiteerana.